We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This guideline represents a departure from previous guidelines because it doesn't focus on specific target levels of low-density lipoprotein cholesterol, commonly known as LDL, or 'bad cholesterol,' although the definition of optimal LDL cholesterol has not changed. Instead, it focuses on defining groups for whom LDL lowering is proven to be most beneficial.”
“From the committee's perspective, after you calculate risk, that's the starting point of a really important risk discussion. It's not the starting point for a prescription. We really wanted to put the patient and doctor back into the equation; really dig in and consider, is this the best approach for this patient who is at risk?”
“First, it ignores a wealth of information on the pathophysiology of the disease process. Second, it presumes that the reason trials are designed is to answer guideline questions. They aren't. Trials are designed by pharmaceutical companies trying to get claims issued on their drugs. More important, the absence of randomized clinical-trial data does not justify inaction if LDL cholesterol remains elevated.”
No takes yet. Share an insight, caveat, or question.
Stone et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: